Every year, more than 8000 new cases of chronic myeloid leukemia (CML) are diagnosed in
the United States. 1 BCR-ABL1, a fusion protein kinase derived from a reciprocal …

Imatinib mesylate was the first tyrosine kinase inhibitor (TKI) approved for the management
of chronic myeloid leukemia. Imatinib produces acceptable responses in approximately 60 …

SHP2 is a cytoplasmic protein tyrosine phosphatase encoded by the PTPN11 gene and is
involved in cell proliferation, differentiation, and survival. Recently, we reported an allosteric …

Traditionally, drugs are monovalent, targeting only one site on the protein surface. This
includes orthosteric and allosteric drugs, which bind the protein at orthosteric and allosteric …

Encoded by PTPN11, the SHP2 (Src homology-2 domain-containing protein tyrosine
phosphatase-2) is widely recognized as a carcinogenic phosphatase. As a promising anti …

A fundamental difficulty in testing “targeted therapies” in acute myeloid leukemia (AML) is
the limitations of preclinical models in capturing inter-and intrapatient genomic …

Chronic myeloid leukemia (CML) is a type of blood cancer that is known to affect
hematopoietic stem cells. The presence of the Philadelphia chromosome (Ph+) is the major …

Since its emergence in early 2019, the respiratory infectious virus, SARS-CoV-2, has
ravaged the health of millions of people globally and has affected almost every sphere of …

We categorize the resistance into BCR–ABL-dependent and BCR–ABL-independent
subgroups to further describe the complex molecular pathways which can potentially serve …

Abstract Asciminib (previously ABL001), which binds the myristate-binding pocket of the Bcr-
Abl kinase domain, is in phase I clinical trials as monotherapy and in combination with …